ModerateVitamin K antagonist anticoagulants×Sulfonamide-trimethoprim combination
Updated · Methodology
Mechanism
In the liver, CYP2C9 is the main enzyme that metabolises acenocoumarol (acenocoumarol summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Sulfamethoxazole, a component of co-trimoxazole, inhibits CYP2C9, and trimethoprim inhibits CYP2C8 (co-trimoxazole prescribing information, US Food and Drug Administration, FDA). According to the Spanish co-trimoxazole SmPC, co-trimoxazole potentiates warfarin through stereoselective inhibition of its metabolism, and sulfamethoxazole can displace warfarin from its binding sites on plasma albumin in vitro. Data exist only for warfarin (co-trimoxazole SmPC, AEMPS). The acenocoumarol SmPCs list sulfonamides, co-trimoxazole included, among the drugs that can potentiate acenocoumarol. Acenocoumarol itself is 98.7% bound to plasma proteins, mainly albumin (acenocoumarol SmPCs, AEMPS). Infection and inflammation can reduce the protein binding of acenocoumarol, so strict medical supervision is needed during such periods (acenocoumarol SmPC, AEMPS).
Symptoms
The main risk is bleeding. According to the US label, co-trimoxazole may prolong the prothrombin time in people receiving warfarin, and hypoprothrombinaemia, a low level of prothrombin in the blood, is among its adverse reactions (co-trimoxazole prescribing information, US Food and Drug Administration, FDA). Acenocoumarol can cause serious bleeding, including haemorrhagic shock, and fatal bleeding. The risk is higher with an international normalised ratio (INR) above 4.0, at age 65 or older and with concomitant treatment (acenocoumarol summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). With excess acenocoumarol, the most frequent signs are bleeding into the skin and blood in the urine. Other signs include bruising, gastrointestinal bleeding, vomiting blood, uterine bleeding, nosebleeds, bleeding gums and bleeding into joints. Fast heartbeat, low blood pressure, nausea, vomiting, diarrhoea and abdominal pain may follow (AEMPS).
Management
The combination is not contraindicated but needs frequent coagulation monitoring. Using warfarin as the example, the Spanish co-trimoxazole SmPC advises careful monitoring of anticoagulant therapy during co-trimoxazole treatment (co-trimoxazole summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The US label says to keep the interaction in mind when giving co-trimoxazole to someone already on anticoagulant therapy. It also says to reassess coagulation by checking the international normalised ratio (INR) and the prothrombin time (co-trimoxazole prescribing information, US Food and Drug Administration, FDA). The same label also says in general terms to avoid co-trimoxazole with substrates of CYP2C8 and CYP2C9. For warfarin, a CYP2C9 substrate, its interaction table gives only prothrombin time and INR monitoring (FDA). The acenocoumarol SmPCs ask for close and frequent coagulation checks, for example twice a week. This applies both when another drug is added and when it is stopped, including after the end of a co-trimoxazole course (acenocoumarol SmPCs, AEMPS). A change in the acenocoumarol dose does not show in the prothrombin time for at least 36 hours. In patients outside the target range, the effect of a dose change is usually assessed after 7–8 days. Base dose adjustments on the total weekly dose, spread as evenly as possible over seven days (AEMPS). With an INR below 4.5 and minor bleeding, such as a short nosebleed or small isolated bruises, temporarily reducing or skipping a dose is often enough. With an INR of 4.5–10 and no significant bleeding, interrupt acenocoumarol. With an INR above 10, interrupt it and give 1–5 mg of vitamin K1 by mouth (AEMPS). In significant bleeding, interrupt acenocoumarol and give 5–10 mg of vitamin K1 intravenously very slowly, no faster than 1 mg per minute. In severe bleeding, replace clotting factors with fresh whole blood, prothrombin complex concentrate or recombinant factor VIIa together with vitamin K1 (AEMPS). After bleeding, restart acenocoumarol once the INR is back in the target range (AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Bactrim (sulfamethoxazole and trimethoprim) prescribing information (2013)– ; DailyMed setid f59d0c04-9c66-4d53-a0e1-cb55570deb62
- AEMPS: Ficha técnica: Acenocumarol, Sintrom 4 mg (nº registro 25670), sección 4.5 (2025)– AEMPS, CIMA, nº registro 25670 (Sintrom 4 mg comprimidos, Merus Labs; texto de la sección 4.5 idéntico en Sintrom 1 mg, nº 58994), revisión 06/2025, sección 4.5
- AEMPS: Ficha técnica: Acenocumarol Aurovitas 4 mg (nº registro 88315), sección 4.5 (2025)– AEMPS, CIMA, nº registro 88315 (Acenocumarol Aurovitas 4 mg comprimidos EFG; texto idéntico en 1 mg, nº 88278), revisión 07/2025, sección 4.5
- AEMPS: Ficha técnica: Acenocumarol, Sintrom 4 mg (nº registro 25670), sección 4.9 (2025)– AEMPS, CIMA, nº registro 25670 (Sintrom 4 mg comprimidos, Merus Labs; texto de la sección 4.9 idéntico en Sintrom 1 mg, nº 58994), revisión 06/2025, sección 4.9
- AEMPS: Ficha técnica: Sulfametoxazol/trimetoprima, Septrin Forte 160 mg/800 mg (nº registro 58501), sección 4.5 (2026)– AEMPS, CIMA, nº registro 58501 (Septrin Forte 160 mg/800 mg comprimidos, Teofarma; ficha común con Septrin Pediátrico, nº 48669 y 48671), revisión 07/2026, sección 4.5